The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.

Novo is set to exit the cancer drug developer in a purchase by another of its shareholders, Boehringer Ingelheim, that could reach $1.43bn.

The medical services app developer welcomed Baidu Capital aboard in a series C-plus round that represents its second nine-figure round.

Eli Lilly, Novartis Venture Fund and AbbVie Ventures are among the contributors to a series A round disclosed as the neurodegenerative disorder drug developer emerged from stealth.

Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.

The Eli Lilly-backed antibody discovery platform developer's shares opened at more than three times their IPO price to net it a valuation topping $15bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Google and existing investor Novo contributed to a series G2 round valuing the precision medicine developer at $8.1bn post-money.

Sidewalk Labs' health provision spinoff took its valuation above $1bn and its overall funding to about $300m in a General Catalyst-led series C round.